An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population.

Hdl Handle:
http://hdl.handle.net/10147/207550
Title:
An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population.
Authors:
Waterhouse, D F; McLaughlin, A M; Sheehan, F; O'Shea, D
Affiliation:
Department of Endocrinology and Metabolism, St Vincent's University Hospital, Elm, Park, Dublin 4, Ireland. Deirdrewaterhouse@ireland.com
Citation:
Ir J Med Sci. 2009 Jun;178(2):161-6. Epub 2009 Jan 8.
Journal:
Irish journal of medical science
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207550
DOI:
10.1007/s11845-008-0269-1
PubMed ID:
19129978
Abstract:
OBJECTIVES: To investigate the prevalence of ATPIII- and IDF-defined metabolic syndrome (MetS) in an Irish screening population and to determine the calculated cardiovascular risk for each group. DESIGN: A total of 1,716 subjects were enrolled over a 12-month period. MAIN OUTCOMES: The ATPIII-defined prevalence of MetS in this population was 13.2%. Using IDF criteria, 21.4% of subjects were identified as having the MetS. Correlation between the two definitions was high; however, IDF criteria identified an additional 9.5% (n = 164) of the population as having MetS, which ATPIII criteria failed to recognise. CONCLUSION: We noted a higher prevalence of MetS in the studied population when defined by IDF criteria. However, those identified by IDF and not by ATPIII definition did not have a higher cardiovascular risk score by either Framingham or European Score than those without MetS. Thus, application of the ATPIII definition of MetS, may be the more practical.
Language:
eng
MeSH:
Adult; Aged; Cardiovascular Diseases/*epidemiology; Cohort Studies; Cross-Sectional Studies; Female; Health Status Indicators; Humans; Ireland/epidemiology; Male; *Mass Screening; Metabolic Syndrome X/chemically induced/*epidemiology; Middle Aged; Prevalence; Questionnaires; Risk Assessment; Risk Factors; Statistics as Topic
ISSN:
1863-4362 (Electronic); 0021-1265 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorWaterhouse, D Fen_GB
dc.contributor.authorMcLaughlin, A Men_GB
dc.contributor.authorSheehan, Fen_GB
dc.contributor.authorO'Shea, Den_GB
dc.date.accessioned2012-02-01T10:31:03Z-
dc.date.available2012-02-01T10:31:03Z-
dc.date.issued2012-02-01T10:31:03Z-
dc.identifier.citationIr J Med Sci. 2009 Jun;178(2):161-6. Epub 2009 Jan 8.en_GB
dc.identifier.issn1863-4362 (Electronic)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid19129978en_GB
dc.identifier.doi10.1007/s11845-008-0269-1en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207550-
dc.description.abstractOBJECTIVES: To investigate the prevalence of ATPIII- and IDF-defined metabolic syndrome (MetS) in an Irish screening population and to determine the calculated cardiovascular risk for each group. DESIGN: A total of 1,716 subjects were enrolled over a 12-month period. MAIN OUTCOMES: The ATPIII-defined prevalence of MetS in this population was 13.2%. Using IDF criteria, 21.4% of subjects were identified as having the MetS. Correlation between the two definitions was high; however, IDF criteria identified an additional 9.5% (n = 164) of the population as having MetS, which ATPIII criteria failed to recognise. CONCLUSION: We noted a higher prevalence of MetS in the studied population when defined by IDF criteria. However, those identified by IDF and not by ATPIII definition did not have a higher cardiovascular risk score by either Framingham or European Score than those without MetS. Thus, application of the ATPIII definition of MetS, may be the more practical.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshCardiovascular Diseases/*epidemiologyen_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshCross-Sectional Studiesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHealth Status Indicatorsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIreland/epidemiologyen_GB
dc.subject.meshMaleen_GB
dc.subject.mesh*Mass Screeningen_GB
dc.subject.meshMetabolic Syndrome X/chemically induced/*epidemiologyen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPrevalenceen_GB
dc.subject.meshQuestionnairesen_GB
dc.subject.meshRisk Assessmenten_GB
dc.subject.meshRisk Factorsen_GB
dc.subject.meshStatistics as Topicen_GB
dc.titleAn examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population.en_GB
dc.contributor.departmentDepartment of Endocrinology and Metabolism, St Vincent's University Hospital, Elm, Park, Dublin 4, Ireland. Deirdrewaterhouse@ireland.comen_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.